Cochrane · systematic review · CD003916

Adjuvant radiotherapy for stage I endometrial cancer

Kong, A, Johnson, N, Kitchener, HC, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library

Gynaecological, Neuro-oncology and Orphan Cancer2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 40%High 3 · 60%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Summary of findings: EBRT versus no EBRT for stage I endometrial cancer

Population: women with stage I endometrial cancer

CD003916.PUB4 (current) · 5 questions

Outcome	Effect	Evidence	Status / GRADE
Death from all causes Summary of findings: EBRT vs no EBRT	HR 0.99 [0.82, 1.2]	2628 participants	Moderate
Endometrial carcinoma‐related death Summary of findings: EBRT vs no EBRT	HR 0.96 [0.72, 1.28]	2965 participants	Moderate
Locoregional recurrence Summary of findings: EBRT vs no EBRT	HR 0.36 [0.25, 0.52]	2965 participants	High
Severe acute toxicity Summary of findings: EBRT vs no EBRT	RR 4.68 [1.35, 16.16]	1328 participants	High
Severe late toxicity Summary of findings: EBRT vs no EBRT	RR 2.58 [1.61, 4.11]	3501 participants	High

Summary of findings: EBRT versus no EBRT for stage I endometrial cancer

Population: women with stage I endometrial cancer

CD003916.PUB3 · 5 questions

Outcome	Effect	Evidence	Status / GRADE
Death from all causes Summary of findings: EBRT vs no EBRT	HR 0.99 [0.82, 1.2]	2628 participants	Moderate
Endometrial carcinoma‐related death Summary of findings: EBRT vs no EBRT	HR 0.96 [0.72, 1.28]	2965 participants	Moderate
Locoregional recurrence Summary of findings: EBRT vs no EBRT	HR 0.36 [0.25, 0.52]	2965 participants	High
Severe acute toxicity Summary of findings: EBRT vs no EBRT	RR 4.68 [1.35, 16.16]	1328 participants	High
Severe late toxicity Summary of findings: EBRT vs no EBRT	RR 2.58 [1.61, 4.11]	3501 participants	High